[{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Clinigen Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2025","type":"Licensing Agreement","leadProduct":"MaaT013","moa":"||Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Clinigen Group","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Clinigen Group"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"EIB","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2025","type":"Financing","leadProduct":"MaaT013","moa":"||Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ EIB","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ EIB"},{"orgOrder":0,"company":"Kurobe","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Kurobe","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Kurobe \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kurobe \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital Ghent","sponsor":"Belgium Health Care Knowledge Centre | University Ghent","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Undisclosed","graph2":"Phase IV","graph3":"University Hospital Ghent","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital Ghent \/ Belgium Health Care Knowledge Centre | University Ghent","highestDevelopmentStatusID":"11","companyTruncated":"University Hospital Ghent \/ Belgium Health Care Knowledge Centre | University Ghent"},{"orgOrder":0,"company":"University Hospital, Tours","sponsor":"Pfizer Inc | International Clinical Trials Association","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University Hospital, Tours","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Tours \/ Pfizer Inc | International Clinical Trials Association","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital, Tours \/ Pfizer Inc | International Clinical Trials Association"},{"orgOrder":0,"company":"University of Milano Bicocca","sponsor":"Genetic s.p.a.","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ITALY","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"University of Milano Bicocca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Milano Bicocca \/ Genetic s.p.a.","highestDevelopmentStatusID":"8","companyTruncated":"University of Milano Bicocca \/ Genetic s.p.a."},{"orgOrder":0,"company":"PENTA Foundation","sponsor":"St George's, University of London | H\u00f4pital Universitaire Robert-Debr\u00e9 | University of Tartu | Consorzio per Valutazioni Biologiche e Farmacologiche | University of Liverpool | Therakind | Bambino Ges\u00f9 Hospital and Research Institute | Servicio Madrile\u00f1o ","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"PENTA Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PENTA Foundation \/ St George's, University of London | H\u00f4pital Universitaire Robert-Debr\u00e9 | University of Tartu | Consorzio per Valutazioni Biologiche e Farmacologiche | University of Liverpool | Therakind | Bambino Ges\u00f9 Hospital and Research Institute | Servicio Madrile\u00f1o ","highestDevelopmentStatusID":"8","companyTruncated":"PENTA Foundation \/ St George's, University of London | H\u00f4pital Universitaire Robert-Debr\u00e9 | University of Tartu | Consorzio per Valutazioni Biologiche e Farmacologiche | University of Liverpool | Therakind | Bambino Ges\u00f9 Hospital and Research Institute | Servicio Madrile\u00f1o "},{"orgOrder":0,"company":"Biocomposites","sponsor":"MCRA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Biocomposites","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Biocomposites \/ MCRA","highestDevelopmentStatusID":"8","companyTruncated":"Biocomposites \/ MCRA"},{"orgOrder":0,"company":"Biocomposites","sponsor":"MCRA","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Dermatology","graph2":"Phase II","graph3":"Biocomposites","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Insert","sponsorNew":"Biocomposites \/ MCRA","highestDevelopmentStatusID":"8","companyTruncated":"Biocomposites \/ MCRA"},{"orgOrder":0,"company":"Biocomposites","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Dermatology","graph2":"Phase II","graph3":"Biocomposites","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Insert","sponsorNew":"Biocomposites \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biocomposites \/ Undisclosed"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"Qatar University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"QATAR","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamad Medical Corporation \/ Qatar University","highestDevelopmentStatusID":"1","companyTruncated":"Hamad Medical Corporation \/ Qatar University"},{"orgOrder":0,"company":"Arizona State University","sponsor":"University of Minnesota","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Neurology","graph2":"Phase II","graph3":"Arizona State University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arizona State University \/ University of Minnesota","highestDevelopmentStatusID":"8","companyTruncated":"Arizona State University \/ University of Minnesota"},{"orgOrder":0,"company":"Parker Institute for Cancer Immunotherapy","sponsor":"Seres Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Oncology","graph2":"Phase I","graph3":"Parker Institute for Cancer Immunotherapy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Parker Institute for Cancer Immunotherapy \/ Seres Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Parker Institute for Cancer Immunotherapy \/ Seres Therapeutics"},{"orgOrder":0,"company":"Christiana Care Health Services","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Christiana Care Health Services","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Christiana Care Health Services \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Christiana Care Health Services \/ Undisclosed"},{"orgOrder":0,"company":"University of Manitoba","sponsor":"Health Sciences Centre Winnipeg","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"CANADA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"University of Manitoba","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Manitoba \/ Health Sciences Centre Winnipeg","highestDevelopmentStatusID":"11","companyTruncated":"University of Manitoba \/ Health Sciences Centre Winnipeg"},{"orgOrder":0,"company":"London Health Sciences Centre Research Institute (Lawson)","sponsor":"London Health Sciences Centre","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"London Health Sciences Centre Research Institute (Lawson)","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"London Health Sciences Centre Research Institute (Lawson) \/ London Health Sciences Centre","highestDevelopmentStatusID":"9","companyTruncated":"London Health Sciences Centre Research Institute (Lawson) \/ London Health Sciences Centre"},{"orgOrder":0,"company":"McMaster University","sponsor":"Physician Services Incorporated | Canadian Institutes of Health Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"McMaster University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McMaster University \/ Physician Services Incorporated | Canadian Institutes of Health Research","highestDevelopmentStatusID":"1","companyTruncated":"McMaster University \/ Physician Services Incorporated | Canadian Institutes of Health Research"},{"orgOrder":0,"company":"University of Mississippi Medical Center","sponsor":"Keystone Pharmacy","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Podiatry","graph2":"Phase I","graph3":"University of Mississippi Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Mississippi Medical Center \/ Keystone Pharmacy","highestDevelopmentStatusID":"6","companyTruncated":"University of Mississippi Medical Center \/ Keystone Pharmacy"},{"orgOrder":0,"company":"WellSpan Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Neurology","graph2":"Phase IV","graph3":"WellSpan Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WellSpan Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"WellSpan Health \/ Undisclosed"},{"orgOrder":0,"company":"Panhandle Eye Group, LLP","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Panhandle Eye Group, LLP","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Panhandle Eye Group, LLP \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Panhandle Eye Group, LLP \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Nephrology","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hamilton Health Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hamilton Health Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Savara","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Savara \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Undisclosed"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Vidacare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Vidacare Corporation","highestDevelopmentStatusID":"9","companyTruncated":"Mayo Clinic \/ Vidacare Corporation"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Immunology","graph2":"Phase II","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seres Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Seres Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Vedanta Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Vedanta Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Massachusetts General Hospital \/ Vedanta Biosciences"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Undisclosed","graph2":"Phase I","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seres Therapeutics \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Seres Therapeutics \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Murdoch Childrens Research Institute","sponsor":"Royal Children's Hospital | Royal Hospital For Women | University of Otago | Sydney Children's Hospitals Network | Monash Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Murdoch Childrens Research Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Murdoch Childrens Research Institute \/ Royal Children's Hospital | Royal Hospital For Women | University of Otago | Sydney Children's Hospitals Network | Monash Health","highestDevelopmentStatusID":"11","companyTruncated":"Murdoch Childrens Research Institute \/ Royal Children's Hospital | Royal Hospital For Women | University of Otago | Sydney Children's Hospitals Network | Monash Health"},{"orgOrder":0,"company":"W.J. Wiersinga, MD, PhD","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"W.J. Wiersinga, MD, PhD","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"W.J. Wiersinga, MD, PhD \/ ZonMw","highestDevelopmentStatusID":"1","companyTruncated":"W.J. Wiersinga, MD, PhD \/ ZonMw"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Vancomycin HCl","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"SER-155","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seres Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Seres Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"SER-155","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seres Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Seres Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"SER-155","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seres Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Seres Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"SER-155","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seres Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Seres Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"SER-155","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seres Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Seres Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"SER-287","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seres Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Seres Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Vedanta Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"VE202","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PureTech Health \/ Vedanta Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"PureTech Health \/ Vedanta Biosciences"}]
Find Clinical Drug Pipeline Developments & Deals for Vancomycin
Details :
The financing aims to advance the clinical development of Xervyteg (MaaT013), which is being evaluated in the late-stage clinical trial studies for the treatment of Graft-versus-Host Disease.
Details :
MaaT and Clinigen signed exclusive long-term licensing agreement and commercial supply agreement for Xervyteg (MaaT013), its first in class treatment proposed for patients with acute GVHD.
Details :
Vancomycin Hydrochloride for Injection is a glycopeptide antibacterial
indicated in adult and pediatric patients (neonates and older) for the treatment
of septicemia.
Product Name : Vancomycin Hydrochloride for Injection
Details :
SER-155 decreases the colonization and abundance of bacterial pathogens, and to enhance epithelial barrier integrity in the GI tract, decreasing the incidence of bloodstream infections.
Details :
SER-155 decreases the colonization and abundance of bacterial pathogens, and to enhance epithelial barrier integrity in the GI tract, decreasing the incidence of bloodstream infections.
Details :
SER-155 decreases the colonization and abundance of bacterial pathogens, and to enhance epithelial barrier integrity in the GI tract, decreasing the incidence of bloodstream infections.
Details :
Vancomycin is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Fractures, Open.
Details :
Vancomycin is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pressure Ulcer.
Details :
VE202 is a first-in-class, orally administered, investigational live biotherapeutic product (LBP) consortium consisting of 16 strains of bacteria, which is investigated for the treatment of ulcerative colitis.
Reset All
